- Home
- WFG vs LEGN Comparison
WFG vs LEGN Comparison
Compare WFG & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WFG
- LEGN
- Stock Information
- Founded
- WFG 1955
- LEGN 2014
- Country
- WFG Canada
- LEGN United States
- Employees
- WFG N/A
- LEGN N/A
- Industry
- WFG
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- WFG
- LEGN Health Care
- Exchange
- WFG Nasdaq
- LEGN Nasdaq
- Market Cap
- WFG 7.8B
- LEGN 9.1B
- IPO Year
- WFG N/A
- LEGN 2020
- Fundamental
- Price
- WFG $91.87
- LEGN $38.19
- Analyst Decision
- WFG Buy
- LEGN Strong Buy
- Analyst Count
- WFG 4
- LEGN 13
- Target Price
- WFG $106.25
- LEGN $81.46
- AVG Volume (30 Days)
- WFG 161.0K
- LEGN 1.6M
- Earning Date
- WFG 10-23-2024
- LEGN 11-12-2024
- Dividend Yield
- WFG 1.39%
- LEGN N/A
- EPS Growth
- WFG N/A
- LEGN N/A
- EPS
- WFG N/A
- LEGN N/A
- Revenue
- WFG $6,283,000,000.00
- LEGN $520,183,000.00
- Revenue This Year
- WFG N/A
- LEGN $110.04
- Revenue Next Year
- WFG $6.67
- LEGN $77.16
- P/E Ratio
- WFG N/A
- LEGN N/A
- Revenue Growth
- WFG N/A
- LEGN 122.96
- 52 Week Low
- WFG $72.35
- LEGN $38.02
- 52 Week High
- WFG $102.40
- LEGN $70.13
- Technical
- Relative Strength Index (RSI)
- WFG 44.16
- LEGN 29.40
- Support Level
- WFG $90.73
- LEGN $38.94
- Resistance Level
- WFG $93.52
- LEGN $41.87
- Average True Range (ATR)
- WFG 2.63
- LEGN 2.20
- MACD
- WFG -0.15
- LEGN -0.30
- Stochastic Oscillator
- WFG 36.36
- LEGN 1.74
About WFG West Fraser Timber Co. Ltd Common stock
West Fraser Timber is a softwood lumber company that also produces wood panels and pulp products. The company produces its wood products globally, with lumber mills in British Columbia, Alberta, Europe, and the southeastern United States. Following its acquisition of Norbord in 2021, West Fraser is now one of the largest oriented strand board, or OSB, producers in the world.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.